ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2392

Donor Derived Cell-Free DNA in Renal Transplants, AlloSure vs. Prospera

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Khalil, Ali, Medical City Dallas Hospital, Dallas, Texas, United States
  • Khan, Salman, Medical City Dallas Hospital, Dallas, Texas, United States
  • Kalu, Erica, Dallas Nephrology Associates, Dallas, Texas, United States
  • Saim, Muhammad, Medical City Dallas Hospital, Dallas, Texas, United States
  • Lerman, Mark J., Medical City Dallas Hospital, Dallas, Texas, United States

Group or Team Name

  • Medical City Dallas Kidney Transplant
Background

The risk for allograft loss remains high due to rejection. Measuring donor cell free DNA has recently become an important noninvasive test for renal allograft injury and rejection. Two of the commercially available tests to measure dd -cfDNA, are Allosure(AS) and Prospera.

Methods

We measured dd -cFDNA in 44 post kidney transplants simultaneously using both tests. Patients were 3 to 50 months post kidney transplant and all samples were drawn for cause. Eleven of the 44 patients had allograft biopsies, see table. All patients had routine labs including trough CNI levels and in some cases DSA and/or BK PCR.

Results

44 patients had side by side dd cf-DNA done using AS and Prospera for cause. There were 5 patients with either ACR 1a or 1b or AMR on biopsy. 6 patients had no rejection on biopsy. Please see image for statistical analysis.

Conclusion

There was no statistical difference between dd -cfDNA as measured by both commercial tests in all 44 patients , including 5 with ACR or AMR and 6 without rejection by biopsy. We acknowledge the number of patients who underwent biopsies were small. Prospera demonstated larger measurements of dd-cfDNA in comparison to AS ,but this was not statistically significant p=0.27. Side by side analysis showed AS had marginally better AUC but no significant differences between diagnostic test characteristics observed. AS had better specificity,PPV, and NPV, but this did not reach statistical significance.

Cell Free DNA in Patients with biopsy
SampleProsperaAllosurebiopsycreatinineDSA
#31.070.96NEG1.37NA
#100.060.19NEG2.32NA
#125.864.6AMR1.5A24,DR4,DR53
#160.660.351a1.45DQ6
#170.360.591a1.53DQ6
#191.210.92NEG2.32NA
#233.692NEG1.27DQ4
#241.21.2AMR/FSGS4.32DQ2
#291.961.8NEG3.48NA
#373.262.21B1.8NA
#431.841.6NEG2.42NA

AUC ROC and Rejection threshold of !%